

# A David Marais

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/324643/publications.pdf>

Version: 2024-02-01

59  
papers

3,904  
citations

236925

25  
h-index

182427

51  
g-index

60  
all docs

60  
docs citations

60  
times ranked

3625  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic and Mechanistic Insights into the Modulation of Circulating Lipoprotein (a) Concentration by Apolipoprotein E Isoforms. <i>Current Atherosclerosis Reports</i> , 2022, , 1.	4.8	2
2	Hypertriglyceridaemia in adolescents may have serious complications. <i>South African Medical Journal</i> , 2022, 112, 307-312.	0.6	0
3	Hypertriglyceridaemia in adolescents may have serious complications.. <i>South African Medical Journal</i> , 2022, 112, 307-312.	0.6	0
4	Novel PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Variants in Patients With Familial Hypercholesterolemia From Cape Town. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 934-943.	2.4	5
5	Cerebrotendinous xanthomatosis without neurological involvement. <i>Journal of Internal Medicine</i> , 2021, 290, 1039-1047.	6.0	12
6	Apolipoprotein E and Atherosclerosis. <i>Current Atherosclerosis Reports</i> , 2021, 23, 34.	4.8	21
7	Adiposity and the development of dyslipidemia in APOE $\epsilon$ 2 homozygous subjects: A longitudinal analysis in two population-based cohorts. <i>Atherosclerosis</i> , 2021, 325, 57-62.	0.8	8
8	Discovering hypertriglyceridaemia. <i>South African Medical Journal</i> , 2021, 111, 697.	0.6	0
9	Familial hypercholesterolaemia in South Africa: A reminder. <i>South African Medical Journal</i> , 2021, 111, 700.	0.6	0
10	Hyperlipidemic myeloma, a rare form of acquired dysbetalipoproteinemia, in an HIV seropositive African female. <i>Clinica Chimica Acta</i> , 2021, 520, 71-75.	1.1	4
11	Homozygous familial hypercholesterolemia and its treatment by inclisiran. <i>Expert Opinion on Orphan Drugs</i> , 2020, 8, 197-208.	0.8	1
12	Validation of PHASE for deriving N-acetyltransferase 2 haplotypes in the Western Cape mixed ancestry population. <i>African Journal of Laboratory Medicine</i> , 2020, 9, 988.	0.6	0
13	Reduced Lipoprotein(a) Associated With the Apolipoprotein E2 Genotype Confers Cardiovascular Protection in Familial Hypercholesterolemia. <i>JACC Basic To Translational Science</i> , 2019, 4, 425-427.	4.1	5
14	Severe hypertriglyceridaemia and pancreatitis in a patient with lipoprotein lipase deficiency based on mutations in lipoprotein lipase (LPL) and apolipoprotein A5 (APOA5) genes. <i>BMJ Case Reports</i> , 2019, 12, e228199.	0.5	6
15	Comparative aspects of the care of familial hypercholesterolemia in the "Ten Countries Study". <i>Journal of Clinical Lipidology</i> , 2019, 13, 287-300.	1.5	32
16	Lomitapide and Mipomersen "Inhibiting Microsomal Triglyceride Transfer Protein (MTP) and apoB100 Synthesis. <i>Current Atherosclerosis Reports</i> , 2019, 21, 48.	4.8	36
17	Apolipoprotein E in lipoprotein metabolism, health and cardiovascular disease. <i>Pathology</i> , 2019, 51, 165-176.	0.6	215
18	Familial hypercholesterolaemia and its management in South Africa. <i>Cardiovascular Journal of Africa</i> , 2019, 30, 247-247.	0.4	0

#	ARTICLE	IF	CITATIONS
19	The mind's eye: A neuro-ophthalmological perspective on Niemann-Pick type C disease. <i>African Vision and Eye Health</i> , 2019, 78, .	0.2	0
20	A Pharmacogenetic Approach to the Treatment of Patients With <i>PPARG</i> Mutations. <i>Diabetes</i> , 2018, 67, 1086-1092.	0.6	30
21	Identification of a single MPV17 nonsense-associated altered splice variant in 24 South African infants with mitochondrial neurohepatopathy. <i>Clinical Genetics</i> , 2018, 93, 1093-1096.	2.0	12
22	Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol. <i>European Heart Journal</i> , 2018, 39, 1162-1168.	2.2	81
23	Severe hypercholesterolaemia with a high risk of atherosclerosis may be precipitated by a high-sterol diet. <i>South African Medical Journal</i> , 2018, 108, 707.	0.6	0
24	Heterozygous familial hypercholesterolaemia in specialist centres in South Africa, Australia and Brazil: Importance of early detection and lifestyle advice. <i>Atherosclerosis</i> , 2018, 277, 470-476.	0.8	6
25	LDL-cholesterol target achievement in patients with heterozygous familial hypercholesterolemia at Groote Schuur Hospital: Minority at target despite large reductions in LDL-C. <i>Atherosclerosis</i> , 2018, 277, 327-333.	0.8	12
26	South African dyslipidaemia guideline consensus statement: 2018 update A joint statement from the South African Heart Association (SA Heart) and the Lipid and Atherosclerosis Society of Southern Africa (LASSA). <i>South African Medical Journal</i> , 2018, 108, 973-1000.	0.6	18
27	Autosomal dominant familial dysbetalipoproteinemia: A pathophysiological framework and practical approach to diagnosis and therapy. <i>Journal of Clinical Lipidology</i> , 2017, 11, 12-23.e1.	1.5	33
28	Familial dysbetalipoproteinemia: an underdiagnosed lipid disorder. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2017, 24, 133-139.	2.3	61
29	Effect of adding bezafibrate to standard lipid-lowering therapy on post-fat load lipid levels in patients with familial dysbetalipoproteinemia. A randomized placebo-controlled crossover trial. <i>Journal of Lipid Research</i> , 2017, 58, 2180-2187.	4.2	14
30	Evolocumab for the treatment of homozygous familial hypercholesterolaemia. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 789-798.	0.8	3
31	PCSK9 Modulates the Secretion But Not the Cellular Uptake of Lipoprotein(a) Ex Vivo. <i>JACC Basic To Translational Science</i> , 2016, 1, 419-427.	4.1	94
32	Marine and terrestrial foods as a source of brain-selective nutrients for early modern humans in the southwestern Cape, South Africa. <i>Journal of Human Evolution</i> , 2016, 97, 86-96.	2.6	23
33	Tendon xanthomas: Not always familial hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2016, 10, 1262-1265.	1.5	14
34	PCSK9 inhibition in LDL cholesterol reduction: Genetics and therapeutic implications of very low plasma lipoprotein levels. , 2015, 145, 58-66.		44
35	Dysbetalipoproteinaemia: A mixed hyperlipidaemia of remnant lipoproteins due to mutations in apolipoprotein E. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2014, 51, 46-62.	6.1	52
36	Nutrition, modernity and the archaeological record: Coastal resources and nutrition among Middle Stone Age hunter-gatherers on the western Cape coast of South Africa. <i>Journal of Human Evolution</i> , 2014, 77, 64-73.	2.6	51

#	ARTICLE	IF	CITATIONS
37	Elevated Plasma PCSK9 Level Is Equally Detrimental for Patients With Nonfamilial Hypercholesterolemia and Heterozygous Familial Hypercholesterolemia, Irrespective of Low-Density Lipoprotein Receptor Defects. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2365-2373.	2.8	57
38	Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. <i>Lancet, The</i> , 2013, 381, 40-46.	13.7	624
39	Dietary lipid modification for mild and severe dyslipidaemias. <i>Proceedings of the Nutrition Society</i> , 2013, 72, 337-341.	1.0	14
40	Recent advances in the treatment of homozygous familial hypercholesterolaemia. <i>Current Opinion in Lipidology</i> , 2013, 24, 288-294.	2.7	20
41	Reduction in Mortality in Subjects With Homozygous Familial Hypercholesterolemia Associated With Advances in Lipid-Lowering Therapy. <i>Circulation</i> , 2011, 124, 2202-2207.	1.6	301
42	Efficacy criteria and cholesterol targets for LDL apheresis. <i>Atherosclerosis</i> , 2010, 208, 317-321.	0.8	115
43	Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2010, 375, 998-1006.	13.7	813
44	Rosuvastatin reduces non-“high-density lipoprotein cholesterol and lipoprotein remnants in patients with dysbetalipoproteinemia (Fredrickson type III hyperlipoproteinemia). <i>Journal of Clinical Lipidology</i> , 2008, 2, 418-425.	1.5	7
45	A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia. <i>Atherosclerosis</i> , 2008, 197, 400-406.	0.8	80
46	Familial hypercholesterolaemia: the Cape Town experience. <i>South African Medical Journal</i> , 2008, 98, 99-104.	0.6	6
47	The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. <i>Atherosclerosis</i> , 2007, 193, 445-448.	0.8	323
48	Severe Hypercholesterolemia in Four British Families With the D374Y Mutation in the PCSK9 Gene. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 2654-2660.	2.4	183
49	Screening for Dysbetalipoproteinemia by Plasma Cholesterol and Apolipoprotein B Concentrations. <i>Clinical Chemistry</i> , 2005, 51, 904-907.	3.2	45
50	The diagnosis and management of familial hypercholesterolaemia. <i>European Review for Medical and Pharmacological Sciences</i> , 2005, 9, 141-9.	0.7	1
51	Familial hypercholesterolaemia. <i>Clinical Biochemist Reviews</i> , 2004, 25, 49-68.	3.3	83
52	Non-denaturing polyacrylamide gradient gel electrophoresis for the diagnosis of dysbetalipoproteinemia. <i>Journal of Lipid Research</i> , 2003, 44, 212-217.	4.2	31
53	Dysbetalipoproteinaemia—clinical and pathophysiological features. <i>South African Medical Journal</i> , 2002, 92, 892-7.	0.6	26
54	Founder mutations in the LDL receptor gene contribute significantly to the familial hypercholesterolemia phenotype in the indigenous South African population of mixed ancestry. <i>Clinical Genetics</i> , 1999, 55, 340-345.	2.0	24

#	ARTICLE	IF	CITATIONS
55	CpG hotspot mutations at the LDL receptor locus are a frequent cause of familial hypercholesterolemia among South African Indians. <i>Clinical Genetics</i> , 1997, 51, 394-398.	2.0	25
56	Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia. <i>Journal of Lipid Research</i> , 1997, 38, 2071-2078.	4.2	107
57	The Apolipoprotein E2(Arg145Cys) Mutation Causes Autosomal Dominant Type III Hyperlipoproteinemia With Incomplete Penetrance. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997, 17, 865-872.	2.4	33
58	Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia. <i>Journal of Lipid Research</i> , 1997, 38, 2071-8.	4.2	85
59	Fatal outcome of homozygous familial hypercholesterolaemia in a black patient. A case report. <i>South African Medical Journal</i> , 1990, 77, 588-90.	0.6	4